

## Overview

### Useful For

Monitoring serum concentrations of topiramate

Assessing compliance

Assessing potential toxicity

### Method Name

[Liquid Chromatography Tandem Mass Spectrometry \(LC-MS/MS\)](#)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum Red

### Specimen Required

**Collection Container/Tube:** Red top (serum gel/SST are **not acceptable**)

**Submission Container/Tube:** Plastic vial

**Specimen Volume:** 1 mL

#### Collection Instructions:

1. Draw blood immediately before next scheduled dose.
2. Centrifuge and aliquot serum into plastic vial; within 2 hours of collection.

### Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

[-Neurology Specialty Testing Client Test Request](#) (T732)

[-Therapeutics Test Request](#) (T831)

### Specimen Minimum Volume

0.5 mL

### Reject Due To

Gross hemolysis	OK
Gross lipemia	OK
Gross icterus	OK

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Serum Red	Refrigerated (preferred)	28 days	
	Ambient	28 days	
	Frozen	28 days	

**Clinical & Interpretive****Clinical Information**

Topiramate is a broad spectrum, antiepileptic drug used for various types of seizures, Lennox-Gastaut syndrome (a type of childhood onset epilepsy), and migraine prophylaxis. Topiramate blocks voltage-dependent sodium channels, potentiates gamma-aminobutyric acid (GABA) activity at some of the GABA receptors, and inhibits potentiation of the glutamate receptor and carbonic anhydrase enzyme, which all contribute to its antiepileptic and antimigraine efficacy.

In general, topiramate shows favorable pharmacokinetics with good absorption (1-4 hours for the immediate-release formulation), low protein binding, and minimal hepatic metabolism. Elimination is predominantly via the kidney, and it is excreted unchanged in the urine with an elimination half-life of approximately 21 hours. As with other anticonvulsant drugs eliminated by the renal system, patients with impaired kidney function exhibit decreased topiramate clearance and a prolonged elimination half-life.

Serum concentrations of other anticonvulsant drugs are not significantly affected by the concurrent administration of topiramate, with the exception of patients on phenytoin whose serum concentrations can increase after the addition of topiramate. Other drug-drug interactions include the coadministration of phenobarbital, phenytoin, or carbamazepine, which can result in decreased topiramate concentrations. In addition, concurrent use of posaconazole and topiramate may result in the elevation of topiramate serum concentrations. Therefore, changes in cotherapy with these medications (phenytoin, carbamazepine, posaconazole, or phenobarbital) may require dose adjustment of topiramate, and therapeutic drug monitoring could assist with this. The most common adverse drug effects associated with topiramate include weight loss, loss of appetite, somnolence, dizziness, coordination problems, memory impairment, and paresthesia.

**Reference Values**

Anticonvulsant: 5.0-20.0 mcg/mL

**Interpretation**

Most individuals display optimal response to topiramate with serum levels 5.0 to 20.0 mcg/mL when used to control seizures. Some individuals may respond well outside of this range or may display toxicity within the therapeutic range; thus, interpretation should include clinical evaluation.

Therapeutic ranges are based on specimens collected at trough (ie, immediately before the next dose).

Toxic levels have not been well established.

---

**Cautions**

This test cannot be performed on whole blood.

**Clinical Reference**

1. Hiemke C, Baumann P, Bergemann N, et al: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. *Pharmacopsychiatry*. 2011 Sept;44(6):195-235
2. Patsalos PN, Berry DJ, Bourgeois BF, et al: Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2008 Jul;49(7):1239-1276
3. Johannessen SI, Tomsom T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? *Clin Pharmacokinet*. 2006;45(11):1061-1075
4. Rifai N, Horvath AR, Wittwer CT, eds: *Tietz Textbook of Clinical Chemistry and Molecular Diagnostics*. 6th ed. Elsevier; 2018

**Performance****Method Description**

Samples are diluted and extracted online by liquid chromatography, with detection by tandem mass spectrometry.(Unpublished Mayo method)

**PDF Report**

No

**Day(s) Performed**

Monday through Friday

**Report Available**

1 to 2 days

**Specimen Retention Time**

14 days

**Performing Laboratory Location**

Rochester

**Fees & Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

---

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

80201

**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
TOPI	Topiramate, S	17713-9

Result ID	Test Result Name	Result LOINC® Value
81546	Topiramate, S	17713-9